PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTING

被引：0
|
作者：
Russell-Jones, D. [1 ]
Buchs, S. [2 ]
Jensen, M. M. [2 ]
Hunt, B. [3 ]
Valentine, W. J. [3 ]
Heller, S. [4 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
[4] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1869
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB39
引用
收藏
页码：A671 / A671
页数：1
相关论文
共 50 条
  • [21] Long-term economic outcomes associated with insulin aspart versus human bolus insulin in type 2 diabetes patients in the Swedish setting
    Valentine, W. J.
    Goodall, G.
    Townsend, C.
    Kotchie, R.
    Nielsen, S.
    Erny-Albrecht, K.
    VALUE IN HEALTH, 2007, 10 (06) : A268 - A269
  • [22] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Subjects with Type 1 Diabetes Using CSII
    Bode, Bruce
    Hyveled, Liselotte
    Tamer, Soren Can
    Ybanez, Patria
    Demissie, Marek
    DIABETES, 2015, 64 : A253 - A253
  • [23] Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes
    Heise, Tim
    Pieber, Thomas R.
    Danne, Thomas
    Erichsen, Lars
    Haahr, Hanne
    DIABETES, 2016, 65 : A239 - A239
  • [24] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [25] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Haahr, Hanne
    Pieber, Thomas R.
    Mathieu, Chantal
    Gondolf, Theis
    Shiramoto, Masanari
    Erichsen, Lars
    Heise, Tim
    CLINICAL PHARMACOKINETICS, 2019, 58 (05) : 639 - 649
  • [26] Improved postprandial glycaemic control with faster-acting insulin aspart in individuals with type 1 diabetes using CSII
    Bode, B. W.
    Hyveled, L.
    Tamer, S. C.
    Ybanez, P.
    Demissie, M.
    DIABETOLOGIA, 2015, 58 : S19 - S19
  • [27] Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster-acting insulin aspart or insulin aspart: a secondary analysis of the CopenFast trial
    Soholm, J. C.
    Norgaard, S. K.
    Norgaard, K.
    Clausen, T. D.
    Damm, P.
    Mathiesen, E.
    Ringholm, L.
    DIABETOLOGIA, 2024, 67 : S229 - S229
  • [28] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Hanne Haahr
    Thomas R. Pieber
    Chantal Mathieu
    Theis Gondolf
    Masanari Shiramoto
    Lars Erichsen
    Tim Heise
    Clinical Pharmacokinetics, 2019, 58 : 639 - 649
  • [29] Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart in elderly and younger adults with type 1 diabetes
    Hovelmann, U.
    Zijlstra, E.
    Stender-Petersen, K.
    Jacobsen, J. B.
    Heise, T.
    Haahr, H.
    DIABETOLOGIA, 2015, 58 : S450 - S450
  • [30] The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
    Leelarathna, Lalantha
    Ashley, Donna
    Fidler, Carrie
    Parekh, Witesh
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (07) : 187 - 197
12345